MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Language impairment in Corticobasal Syndrome: from clinical phenotype to biomarkers

J. Parmera, M. Oliveira, A. Coutinho, I. de Almeida, C. Carneiro, A. Neto, R. Nitrini, C. Buchpiguel, E. Barbosa, S. Brucki (São Paulo, Brazil)

Meeting: MDS Virtual Congress 2021

Abstract Number: 584

Keywords: Corticobasal degeneration (CBD), Positron emission tomography(PET), Primary progressive aphasia

Category: Parkinsonism, Atypical: PSP, CBD

Objective: To investigate the language impairment profile of patients diagnosed as probable Corticobasal Syndrome (CBS) [1] in light of a multimodal imaging biomarkers analysis, namely brain atrophy patterns, functional and disease-specific imaging biomarkers.

Background: CBS is a neurodegenerative disease related to multiple underlying pathologies [2]. Besides movement disorders and cognitive deficits, it is recognized that language and speech are also commonly impaired [1]. Previous studies described a phenotype similar to the non-fluent variant of primary progressive aphasia [3], whereas others have reported a wide variety of phenotypes [4,5].

Method: Thirty-one patients with probable CBS were prospectively enrolled. A comprehensive language/speech evaluation was performed. They underwent [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) and [11C]Pittsburgh Compound-B (PIB-PET) on a PET-MRI to assess their amyloid status. Brain atrophy patterns were analyzed using voxel-based morphometry (VBM), and FDG-PET quantitative group analyses were performed at SPM8. A healthy control-group of 30 subjects, matched by age and education, was also included.

Results: CBS patients with amyloid-positive (CBS-A+,13) and negative imaging (CBS-A-,18) did not differ significantly in demography (Table 1). CBS-A+ group demonstrated a worse performance in the general cognitive assessment, mostly in attention, memory, and visuospatial domains (table 1). Both groups did not differ concerning the language cognitive tests, such as the Western Battery aphasia-Revised and verbal fluency tasks. Noteworthy, CBS-A- patients displayed dysarthria more often than CBS-A+ (p=0.008) (figure 1). CBS patients had frontoparietal and basal ganglia hypometabolic patterns compared to controls (figure 2 (a)). Patients with dysarthria showed hypometabolism in the left inferior and middle frontal gyrus, and left thalamus and caudate (figure 2 (b)). They also demonstrated brain atrophy at bilateral caudate and left supplementary motor area (SMA) (figure 3 (b)).

Conclusion: Language impairment in CBS is  highly heterogeneous. Dysarthria may be a valuable clinical clue suggesting underlying pathology, probably more related to CBS due to tauopathies than  Alzheimer’s disease. Left frontal areas, the SMA, and basal ganglia might play a role in manifesting speech disorders related to tauopathies.

Table1

Figure1

Figure3

Figure2

References: [1] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496–503. [2] Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54: 15–9. [3] Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009; 24: 1593–9. [4] Peterson KA, Patterson K, Rowe JB. Language impairment in progressive supranuclear palsy and corticobasal syndrome. J Neurol 2019. [5] Burrell JR, Hornberger M, Villemagne VL, Rowe CC, Hodges JR. Clinical Profile of PiB-Positive Corticobasal Syndrome. PLoS One 2013; 8.

To cite this abstract in AMA style:

J. Parmera, M. Oliveira, A. Coutinho, I. de Almeida, C. Carneiro, A. Neto, R. Nitrini, C. Buchpiguel, E. Barbosa, S. Brucki. Language impairment in Corticobasal Syndrome: from clinical phenotype to biomarkers [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/language-impairment-in-corticobasal-syndrome-from-clinical-phenotype-to-biomarkers/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/language-impairment-in-corticobasal-syndrome-from-clinical-phenotype-to-biomarkers/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley